Literature DB >> 35261451

Endogenous endophthalmitis due to methicillin-resistant Staphylococcus aureus bacteremia in a patient with COVID-19.

Tim Brotherton1, Eugene Nwankwo1, Debapria Das2, Adam Fritz1.   

Abstract

Endogenous endophthalmitis is a rare condition that carries a high risk of vision loss. Risk factors for developing endogenous endophthalmitis include having a systemic source of infection and one or more risk factors for immunosuppression. We present a case of a 34-year-old man with methicillin-resistant Staphylococcus aureus bacteremia and COVID-19 pneumonia who was treated with corticosteroids and subsequently developed endogenous endophthalmitis.
Copyright © 2021 Baylor University Medical Center.

Entities:  

Keywords:  COVID-19; Corticosteroids; dexamethasone; endophthalmitis; immunosuppression; infectious disease; ophthalmology

Year:  2021        PMID： 35261451      PMCID： PMC8865298          DOI： 10.1080/08998280.2021.1990823

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


  10 in total

1.  Bacterial Endogenous Endophthalmitis in Bacteremic Inpatients.

Authors:  Greg Budoff; Loka Thangamathesvaran; Marco A Zarbin; Neelakshi Bhagat
Journal:  Ophthalmol Retina       Date:  2019-06-20

2.  Vitreous penetration of levofloxacin in the uninflamed phakic human eye.

Authors:  E N Herbert; I A Pearce; J McGalliard; D Wong; C Groenewald
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

Review 3.  Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions.

Authors:  Michelle C Callegan; Michael Engelbert; David W Parke; Bradley D Jett; Michael S Gilmore
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

4.  Endogenous endophthalmitis in the setting of Covid-19 infection: A Case Series.

Authors:  Alper Bilgic; Aditya Sudhalkar; Jesus H Gonzalez-Cortes; Francesc March de Ribot; Rohit Yogi; Laurent Kodjikian; Thibaud Mathis
Journal:  Retina       Date:  2021-03-09       Impact factor: 4.256

Review 5.  Bacterial and Fungal Endophthalmitis.

Authors:  Marlene L Durand
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

6.  Risk factors predictive of endogenous endophthalmitis among hospitalized patients with hematogenous infections in the United States.

Authors:  Kamyar Vaziri; Suzann Pershing; Thomas A Albini; Darius M Moshfeghi; Andrew A Moshfeghi
Journal:  Am J Ophthalmol       Date:  2014-12-06       Impact factor: 5.258

Review 7.  Management of bacterial postoperative endophthalmitis and the role of vitrectomy.

Authors:  Ben Clarke; Thomas H Williamson; Giampaolo Gini; Bhaskar Gupta
Journal:  Surv Ophthalmol       Date:  2018-02-15       Impact factor: 6.048

Review 8.  Endophthalmitis.

Authors:  M L Durand
Journal:  Clin Microbiol Infect       Date:  2013-03       Impact factor: 8.067

9.  Endogenous Endophthalmitis A Complication of COVID-19 Pandemic: A Case Series.

Authors:  Manisha Agarwal; Mani Sachdeva; Surendra Pal; Harita Shah; Madhu Kumar R; Alay Banker
Journal:  Ocul Immunol Inflamm       Date:  2021-07-13       Impact factor: 3.070

10.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.